The diabetes medicine sales in South Korea have shown a consistent growth from 2013 to 2023, with a gradual decrease in the year-on-year growth rate from 10.61% in 2013 to 7.05% in 2023. The Compound Annual Growth Rate (CAGR) has also seen a decrease, from 6.95% in 2013 to 8.53% in 2023, indicating a slowing but steady growth. The forecast for 2028 suggests a further slowdown in growth, with a 5-year CAGR of 4.37% and a total growth rate of 23.87% over the five years.
Looking ahead, factors such as advancements in diabetes treatment, changes in healthcare policy, and demographic shifts in South Korea will be critical in shaping the future market trend for diabetes medicines. Companies should monitor these trends closely to adapt their strategies accordingly.
